These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21086021)

  • 1. Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
    Becker RC; Mahaffey KW; Yang H; Marian AJ; Furman MI; Michael Lincoff A; Hazen SL; Petersen JL; Reist CJ; Kleiman NS;
    J Thromb Thrombolysis; 2011 Feb; 31(2):146-53. PubMed ID: 21086021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.
    Silvain J; O'Connor SA; Yan Y; Kerneis M; Hauguel-Moreau M; Zeitouni M; Overtchouk P; Ankri A; Brugier D; Vicaut E; Ecollan P; Galier S; Collet JP; Montalescot G;
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):503-511. PubMed ID: 30144017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
    Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
    Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation.
    Ray MJ; Juneja M; Bett N; Walters DL
    EuroIntervention; 2009 Aug; 5(3):330-5. PubMed ID: 19736157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
    Spencer FA; Ball SP; Zhang Q; Liu L; Benoit S; Becker RC
    J Thromb Thrombolysis; 2000 Apr; 9(3):223-8. PubMed ID: 10728020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
    Becker RC; Spencer FA; Gibson M; Rush JE; Sanderink G; Murphy SA; Ball SP; Antman EM;
    Am Heart J; 2002 May; 143(5):753-9. PubMed ID: 12040334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor pathway inhibitor release induced by defibrotide and heparins.
    Cella G; Sbarai A; Mazzaro G; Motta G; Carraro P; Andreozzi GM; Hoppensteadt DA; Fareed J
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):225-8. PubMed ID: 11441984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
    Naumnik B; Borawski J; Myśliwiec M
    Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
    Bara L; Bloch MF; Zitoun D; Samama M; Collignon F; Frydman A; Uzan A; Bouthier J
    Thromb Res; 1993 Mar; 69(5):443-52. PubMed ID: 8388583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
    Hoppensteadt D; Fareed J; Klein AL; Jasper SE; Apperson-Hansen C; Lieber EA; Katz WE; Malouf JF; Stoddard MF; Pape LA;
    Am J Cardiol; 2008 Oct; 102(7):842-6. PubMed ID: 18805108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
    Gurfinkel E; Duronto E; Colorio C; Bozovich G; Cohen M; Mautner B
    J Thromb Thrombolysis; 1999 Oct; 8(3):227-32. PubMed ID: 10500313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
    Renda G; Di Pillo R; D'Alleva A; Sciartilli A; Zimarino M; De Candia E; Landolfi R; Di Giammarco G; Calafiore A; De Caterina R
    Haematologica; 2007 Mar; 92(3):366-73. PubMed ID: 17339186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.
    Al Otair HA; Abdel Gader AG; Khurshid SM; Alzeer AH; Al Momen AK; Al Shaikh M; Al Gahtani F; Al Aseri ZA; Abdelrazik HA
    Turk J Haematol; 2016 Jun; 33(2):112-8. PubMed ID: 26377606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
    Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
    Deal EN; Hollands JM; Riney JN; Skrupky LP; Smith JR; Reichley RM
    J Thromb Thrombolysis; 2011 Aug; 32(2):188-94. PubMed ID: 21465129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.
    Xiao Z; Théroux P
    Circulation; 1998 Jan; 97(3):251-6. PubMed ID: 9462526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of anticoagulation in acute coronary syndromes.
    Latour-Pérez J; de-Miguel-Balsa E
    Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.